Conference Description
Abstract Submission
Program Agenda
Accommodations for Disabilities

Vivax Malaria Research III: 2009 and Beyond

May 24 - 28, 2009
Gamboa Rainforest Resort, Panama

Sponsored by





Conference Description

The purpose of the conference is to assess our current knowledge of vivax malaria and to prioritize the critical needs for development of effective prophylactic and curative therapies. Bringing together this interest group, representing the broad global and regional aspects of vivax malaria, provides a significant venue to evaluate the status of the field and to identify the priorities for research.

A comprehensive view will be obtained about what we currently know about vivax malaria to identify critical gaps in our knowledge. Discussions are included to formulate consensus viewpoints on fundamental aspects of the parasite (biology, pathogenesis, epidemiology, therapy, etc.) and to identify important topics where too little is known to form a consensus. As a result of this conference, a report will be produced that summarizes the consensus of the conference discussions and the conclusions to help guide allocation of resources for research and prevention.

Conference online registration will begin January 5th, 2009 and continue until maximum capacity of 120 is reached.



Program Agenda

May 24, Sunday




Gamboa Rainforest Resort lobby




Janine Hartfield, Nikki LeClair



Opening Ceremony

Grand Ballroom



John Adams

Welcome to VMR3 conference



Julio Escobar

Secretary General of Science, Technology and Innovation 



Mario Rodriguez

A new initiative to eradicate malaria in Mesoamerica



Ric Price

Challenges for eliminating P. vivax from the Asia-Pacific region



Opening reception 

Gamboa Rainforest Resort back patio

May 25, Monday
630 breakfast buffet
The biology of vivax malaria and its vectors Chairs: Barbara Sina, Mario Rodriguez
800 B1 John Adams VMR3 conference goals and agenda
815 B2 Carlos Guerra A Preliminary map of the global distribution and intensity of transmission of Plasmodium vivax malaria
845 B3 Dennis Shanks Planning for Malaria Elimination / Eradication especially Plasmodium vivax in Asia
900 B4 AP Dash Vivax malaria: Indian Perspective 
915 B5 Goa Qi Susceptibility vivax to Anopheles anthrophagus from different areas in China
930 B6 Jose Eduardo Calzada Genetic diversity studies of Plasmodium vivax circulating in Panamanian endemic areas
945 B7 Chae Sung Lim The molecular characteristics of P. vivax in Korea isolated from 1996 to 2008. 
1000     break
1030 B8 Akira Kaneko P. vivax resurgence a decade after malaria elimination on Aneityum island
1045 B9 Ghulam Rahim Awab Comparative efficacy and safety of dihydroartimisinin-piperaquine (DHA-PQP) for the treatment of vivax malaria
in Afghanistan
1100 B10 Sylvie Manguin Trend of vivax malaria in Southwest Asia for the past 40 years with a focus on Thailand and its malaria vectors.
1115 B11 Robert Zimmerman Seasonal Abundance of Anopheline Mosquitoes and Their Association with rainfall and malaria along the Matapi River, Amapa, Brazil
1130 B12 Yasmin Rubio-Palis Plasmodium vivax prevalence in anophelines from Venezuela
1145 B13 Maria Mota Identification of host factors and lead compounds for development of novel agents targeting Plasmodium-infect hepatocytes – can they be used to target hypnozoite stages?
1200 B14 TBA short talks
1230 lunch in Los Guayacanes
Molecular & immunobiology of vivax malaria Chairs: Socrates Herrera, Ashis Das
1400 C1 Nic Anstey How does P. vivax cause severe malaria?
1430 C2 Socrates Herrera Plasmodium vivax CS Protein Clinical Trials in Colombia
1445 C3 Luzia Carvalho Inhibitory antibodies to Plasmodium vivax Duffy binding protein are allele-specific following a single malaria infection
1500 C4 Ivo Mueller Differential acquisition of immunity to P. vivax and
P. falciparum In Papua New Guinean children
1515 C5 Chris King Correlates of Acquired Immunity to Plasmodium vivax
Duffy Binding Protein
1530 C6 John Adams B-cell epitopes associated with naturally acquired inhibition of the Plasmodium vivax Duffy binding protein
1545 C7 Osamu Kaneko P. vivax STP1 (SURFIN homolog) polymorphism and
human sera reactivity
1600     break 
1630 C8 Balbir Singh Genetic diversity of P. knowlesi
1645 C9 Peter Zimmerman Reduced susceptibility to Plasmodium vivax malaria in association with red blood cell polymorphisms
in Papua New Guinea
1700 C10 Ashis Das Molecular analysis of Plasmodium vivax parasites involved in severe manifestations
1715 C11 Liwang Cui Plasmodium vivax: global genetic diversity and local microheterogeneity
1730 C12 YD Sharma Biochemical and Molecular Characterization of Aspartic protease gene (PvPM4) from Plasmodium vivax in India
1745 C13 Kesinee Chotivanich P. vivax-infected red cells adhere to glycosaminoglycans
1800 C14 TBA short talks
1830     discussion groups
1930   dinner
2030   P1 posters
May 26, Tuesday
630   breakfast buffet
Genomics and genetics of P. vivax Chairs: Jane Carlton, Hernando del Portillo
800 John Adams today's agenda
805 D1 Jane Carlton The study of Plasmodium vivax in the age of genomics
830 D2 Zbynek Bozdech Comparative analyses of the Plasmodium vivax transcriptome to other Plasmodium species.
845 D3 Nadira Karunaweera Microsatellite Diversity in Plasmodium vivax field parasite isolates
900 D4 Marcelo Ferreira Population structure and evolution of Plasmodium vivax diversity in rural Amazonia
915 D5 Ananis Escalante The evolution and distribution of primate malarias
in South East Asia
930 D6 Lilia Gonzalez-Ceron Analysis of polymorphic genetic markers identified Plasmodium vivax relapeses of variable interval time in a malaria transmission focus of Southern Chiapas, Mexico
945 D7 Jung-Yeon Kim Long-term and multiple analysis of genetic diversity on
re-emerged P. vivax in Korean peninsula:  
current malaria is endemic?
1000     break
1030 D8 Rick Fairhurst Does hemoglobin E influence the pathogenesis
of P. vivax malaria?
1045 D9 Anavaj Sakuntabhai Human Genetic susceptibility to Plasmodium vivax 
1100 D10 Hernando del Portillo Role of the spleen in reticulocyte-prone non lethal malaria
1115 D11 Peter Preiser Understanding the biological role of the pir multigene family
in Plasmodium.
1130 D12 David Roos PlasmoDB: New data, new features, and new functionality
for data mining
1200 D13 TBA short talk
1230 lunch in Los Guayacanes
Obstacles & opportunities for P. vivax drug therapy Chairs: Qin Cheng, Nicanor Obaldia
1400 E1 Ric Price Chloroquine-Resistance is emerging on the
Thai Myanmar border
1430 E2 Marcus Lacerda Treatment of Vivax Malaria in Latin America
1445 E3 Jae-Won Park Changing Pattern of chloroquine- susceptibility of
Plasmodium vivax in the Republic of Korea
1500 E4 Qin Cheng Dissecting Drug Resistance in P. vivax 
1515 E5 Chairat Uthaipibul Plasmodium models for anti-P. vivax DHFR-TS screening
1530 E6 Carmenza Spadafora ICBG natural products drug discovery program for new antimalarials
1545 E7 Nicanor Obaldia Evaluation of Drug and Vaccine candidates in the Human
P. falciparum and P. vivax Malaria/Aotus Monkey model
1600     break
1630 E8 Dennis Kyle Opportunities for liver stage drug development
1700 E9 Clemens Kocken Plasmodium cynomolgi: in vivo and in vitro models for
P. vivax liver stage drug development
1715 E10 Dominique Mazier Towards a rational design of a hepatocyte cell line permissive to complete maturation of P. falciparum and P. cynomolgi
1730 E11 Soundarapandian Velmurugan New Tools for Attacking the Liver Stage of Plasmodium vivax
1745 E12 Jetsum Prachumsri Research on the Plasmodium vivax parasite to support drug and vaccine development
1800 E13 Geoffery Dow Radical Cure and Anti-Relapse Efficacy of Tafenoquine Drug Combinations Against P. cynomolgi Malaria
in Rhesus Macaques
1800 E14 Wil Milhous Summary:  how did we get to where we are?
1815 E15 TBA short talk
1830     discussion groups
1930   dinner
2030   P2 poster session 
sponsored by the Gorgas Memorial Institute
May 27, Wednesday
630 breakfast buffet
Vaccines, clinical trials, models Chairs: Laurent Renia, Yimin Wu
800 John Adams today's agenda
805 F1 John Barnwell Some New Non-human Primate Models for Vivax Malaria Research and How to evaluate P vivax vaccines
830 F2 Myriam Arevalo-Herrera Aotus model as a model for Plasmodium vivax vaccine studies
845 F3 Ruobing Wang Vivax Malaria Vaccine Development: taking cues from nature
900 F4 Laurent Renia Plasmodium vivax immunity: identifying correlates of protection & Exploring the Nanoterrain and Biomechanics
of P. vivax IRBCs
915 F5 Maricio Rodrigues New malaria vaccine candidates based on the Plasmodium Merozoite Surface Protein-1 and the innate immune response agonist Salmonella typhimurium FliC flagellin
930 F6 Anjali Yadava Pre-Clinical Development of a Pre-erythrocytic vaccine
for P. vivax
945 F7 Jon Daugherty Regulatory Perspectives on Plasmodium vivax Malaria
Vaccine Development
1000     break
1030 F8 Takafumi Tsuboi Wheat germ cell-free protein synthesis system: a breakthrough for the post-genome malaria vaccine candidate discovery
1045 F9 Mary Galinski P. vivax target discovery: the promise and perils of in vivo
and in vitro models
1100 F10 Niraj Tolia Dimerization is important for the interaction of P. vivax Duffy binding proteiin with the host receptor Duffy Antigen Receptor for Chemokines
1115 F11 Yimin Wu Transmission Blocking Vaccine for Vivax Malaria
1130 F12 Joe Vinetz Designing Transmission-Blocking Malaria Vaccine Trials for Plasmodium vivax malaria
1145 F13 TBA short talks
1230   lunch
1830     discussion groups
1230   lunch
2030   culture workshop Kesinee Chatovanich, Tetsuya Furuya, Qi Gao, Eun-Taek Han, Tasanee Panichakul, Ubalee Ratawan, Louis Schofoeld, Nongnuch Yimamnuaychoke
2030   bioinformatic workshop  Omar Harb
May 28, Thursday
630     breakfast buffet
  Community resources Chairs: Jane Carlton, Barbara Sina
800   John Adams today's agenda
810   various funding mechanisms for research & training: NIH, WHO, MMV, MVI, BMGF, WT
    various community networking and support groups
    TBA other resources for the research community
1000     break
Summary John Adams
    focus groups epidemiology, vectors, envirnmental control
      diagnosis, clinical management
      immunity preclinical discovery, vaccine development
      drugs, resistance,target , development
1230     lunch
1400 final chance to network and plan collaborative studies
Conference program will end at 2 PM.


Important Information to Consider for Travel to Panama

What are the requirements to enter Panama?

For more information – please go to:


Additional requirements vary according to nationality and are subject to change. Citizens from certain countries need a tourist card, others need an authorized visa and others do not need anything.

If you are flying into Panama the most probable scenario is that you will not be asked to show a return ticket and in case you are, be sure to at least have a return ticket valid within 1 year of entering the country. If you plan to be in Panama for more than 90 days, then it is likely that you will be applying for some type of visa after entering the country and the authorities may have a few questions about your intentions. In this case you should be able to explain your plans and then allowed to enter the country after correctly informing the authorities about what you want to do.

If you enter Panama by bus or by boat you will have to purchase a return ticket by land or by water because the authorities may ask for it and if you do not have it you will run into unnecessary trouble and you will end up buying it anyways. If you expect to leave the country in a different way then the way that you plan to enter Panama and you still do not have that return ticket, then our advice is that you purchase any return ticket. For example, if you enter Panama through Costa Rica by bus, but plan to leave by plane and you still have not bought that ticket, then just buy the cheap bus ticket: it will only cost you $10 and you will avoid any unpleasant situation.

Do I need a Visa to enter Panama?

It depends on your nationality. Citizens from the following countries DO NOT need a visa to enter Panama because their countries hold treaties with Panama that entitle their citizens to visit for up to 90 days without a visa:







Costa Rica


El Salvador























Citizens from these countries can apply for an extension for up to another 30, 60 or 90 days. Petitions are approved or denied on a case-by-case basis. Immigration recommends you apply at least a week before your time is up.

Citizens from all other nationalities either need a Tourist Card or some other type of Visa.

Do I need a Tourist Card to enter Panama?

If you can enter the country without a visa, you certainly do not need a Tourist Card. A tourist card is basically a piece of paper or a simple form that you fill out and purchase for only $5. No worries, if you are entitled to a tourist card no one will say no unless you are a wanted criminal!
Nationals from the following countries DO REQUIRE a tourist card (US $5), available from Panamanian embassies and consulates, airlines serving Panama, border crossings, or at the international airport:

























New Zealand

San Marino

South Korea







In other words, if you are on this list, do not bother going to a consulate or embassy to get a tourist card: once you are on your flight you will probably be given one and if not, when you land on Tocumen Airport you will be able to purchase one before going through immigration.

Nationals from these countries:






Dominican Republic


require tourist visas and should contact an embassy or consulate before coming to Panama.

The law reducing the term of the tourist card to 30 days is still on the books BUT the immigration authority enforcement division has informed us that the policy since 1/1/08 is to allow citizens from U.S.A. and Canada a 90 days Tourist Card just like before, in other words, the same amount of time as those citizens who do not require a visa or a tourist card. Citizens from all other countries that enter Panama with a tourist card are only entitled to stay for a maximum of 30 days unless they request an extension.

Citizens from these countries can apply for an extension for up to another 30, 60 or 90 days. Petitions are approved or denied on a case-by-case basis. Immigration recommends you apply at least a week before your time is up.





Go beyond the expected resort experience at Gamboa Rainforest Resort. From this beautiful luxury hotel, you have immediate access to Panama's pristine rainforest and the Panama Canal.

You can explore miles and miles of the Soberania National Park, meeting wild exotic birds and monkeys on expertly guided tours and then return to the comforts of resort luxury.

Gamboa Rainforest Resort brings you luxury in the jungle. The lodge was built in the year 2000 with spacious modern rooms according to the highest hotel standards.



Accommodations for Disabilities

Please notify the CPD Office, 12901 Bruce B. Downs Blvd., MDC Box 60, Tampa, Florida, 33612 or call (813) 974-4296 a minimum of ten working days in advance of the event if a reasonable accommodation for a disability is needed.

Events, activities and facilities of the University of South Florida are available without regard to race, color, sex, national origin, disability, age, or Vietnam veteran status as provided by law and in accordance with the University's respect for personal dignity.


Course Menu Medical Resources CPD Info